



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.

Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated May 08, 2018**

To,  
BSE Limited  
National Stock Exchange of India Limited  
**Symbol: GRANULES Scrip Code: 532482**

**Sub: Received approval for ANDA filed by Granules India Limited.**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India Limited for Methocarbamol Tablet 500 mg and 750 mg. The approved ANDA is the bioequivalent and therapeutically equivalent to Reference Listed Drug (RLD) of Robaxin 500 mg and 750 mg of Auxilium Pharmaceuticals, LLC. Granules India Limited intends to commercialise this product shortly.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

**FOR GRANULES INDIA LIMITED**

*Chaitanya Tummala*

**CHAITANYA TUMMALA  
COMPANY SECRETARY  
COMPLIANCE OFFICER**

